Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"
Antenatal corticosteroids result in substantial decrease in neonatal morbidity and mortality by specifically reducing the risk of respiratory distress syndrome, intraventricular hemorrhage and neonatal death among premature infants. No human randomized study has formally compared betamethasone and dexamethasone, the preferred corticosteroids for antenatal therapy, with regards to their effectiveness in reducing neonatal morbidities and mortality. Our objective was to compare betamethasone with dexamethasone in terms of effectiveness in reducing perinatal morbidities and mortality among preterm infants.
Respiratory Distress Syndrome
Drug: Betamethasone(Celestone soluspan) and Dexamethasone
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Respiratory distress syndrome
- Intraventricular hemorrhage
- Neonatal mortality
- Periventricular leukomalacia
- Necrotizing enterocolitis
- Neonatal sepsis
|Study Start Date:||August 2002|
|Estimated Study Completion Date:||April 2005|
We conducted a double blind placebo-controlled randomized trial of antenatal betamethasone compared to dexamethasone among women at risk of preterm deliveries at Stony Brook University Hospital from August 1, 2002 through July 31, 2004. We excluded women with clinical chorioamnionitis, major fetal structural anomalies, fetal chromosomal abnormalities, prior antenatal steroid exposure, and use of betamethasone or dexamethasone for other medical indications, quadruplets and higher order multiple gestation and those who declined enrollment. Consenting women were randomly allocated to one of two groups by the Pharmacy using computer generated random numbers. The statistical analysis was performed in accordance of the intention-to-treat principle. Student t test, Chi square and Fisher exact test were used for analysis. A P value of < .05 was considered statistically significant.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00418353
|United States, New York|
|Stony Brook University Hospital|
|Stony Brook, New York, United States, 117913|
|Principal Investigator:||Andrew A Elimian, M.D||Stony Brook University|